Monday, June 22, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 739 of 1,261
  1. US 9102948

    Regulating alkaloids

    22ND CENTURY LIMITED, LLC · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  2. US 9102698

    Process for the synthesis of IB-MECA

    CAN-FITE BIOPHARMA LTD. · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  3. US 9102940

    RNAi modulation of SCAP and therapeutic uses thereof

    The Board of Regents of the University of Texas System · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  4. US 9102831

    Process for producing improved zein articles

    The United States of America, as represented by the Secretary of Agriculture · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  5. US 9102672

    Azaindole derivatives as CFTR modulators

    Vertex Pharmaceuticals Incorporated · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  6. US 9102938

    2′ and 5′ modified monomers and oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  7. US 9102666

    Methods and drug products for treating Alzheimer's disease

    Takeda Pharmaceutical Company Limited · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  8. US 9102626

    Multifunctional radical quenchers for the treatment of mitochondrial dysfunction

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  9. US 9101660

    Solid preparation

    Takeda Pharmaceutical Company Limited · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  10. US 9102660

    Process of making prostacyclin compounds with linker thiol and pegylated forms

    United Therapeutics Corporation · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  11. US 9101612

    Secondary structure stabilized NMDA receptor modulators and uses thereof

    Northwestern University · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  12. US 9101637

    Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity

    The Board of Regents of the University of Texas System · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  13. US 9101643

    Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)

    Alnylam Pharmaceuticals, Inc. · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  14. US 9101600

    Compounds as RORγt modulators and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  15. US 9101636

    Methods and compositions for self-regulated release of active pharmaceutical ingredient

    Acurx Pharmaceuticals, Inc. · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  16. US 9101575

    Methods of inhibiting vascular permeability and apoptosis

    UNIVERSITY OF CONNECTICUT · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  17. US 9102744

    Conjugated anti-CD38 antibodies

    Takeda Pharmaceutical Company Limited · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  18. US 9101670

    Conjugates of an anti-TNF-α antibody

    Nektar Therapeutics · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  19. US 9102620

    Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  20. US 9101601

    Methods of treating or preventing insulin resistance and associated diseases and conditions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 11, 2015 · Expires Aug 6, 2035

    granted
  21. CA 2938043

    MELANGE GAZEUX NO/HE A ACTION BACTERICIDE

    AIR LIQUIDE SANTE (INTERNATIONAL) [FR] · Granted Aug 6, 2015 · Expires Aug 1, 2035

    granted
  22. US 9096542

    Kinase inhibitors and their uses

    Rigel Pharmaceuticals, Inc. · Granted Aug 4, 2015 · Expires Jul 30, 2035

    granted
  23. US 9095622

    Oligomer-protein tyrosine kinase inhibitor conjugates

    Nektar Therapeutics · Granted Aug 4, 2015 · Expires Jul 30, 2035

    granted
  24. US 9095620

    Reagents

    Nektar Therapeutics · Granted Aug 4, 2015 · Expires Jul 30, 2035

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.